AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$XERS

Hecht Beth sold $141K of XERS

Hecht Beth (See Remarks) sold 16,666 shares of Xeris Biopharma Holdings, Inc. (XERS) at $8.49 ($0.14M total) on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hecht Beth
Published Sep 1, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 10:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$XERS
Neutral
high confidence
Mentioned
$XERS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XERSNeutralLow
01

Why it matters

The sale is modest and pre-arranged, suggesting no immediate material impact on XERS stock price.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical data could influence insider's timing.

Relevance 3/10Novelty 4/10Timing: today

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency on insider holdings.

Company-level read

Ticker impact

$XERSNeutralHigh confidence
Context

Officer Beth Hecht sold 16,666 shares of Xeris Biopharma Holdings for $141,434 via a 10b5-1 plan.

Expected impact

Minimal short-term price pressure; likely no significant move.

Evidence & confidence

The transaction represents ~1.5% of the insider's remaining holdings and is a routine pre-arranged sale.

Market effects

Sector

Limited impact on biotech sector; typical insider sale.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Insider may be diversifying; could be a subtle bearish signal.

Key entities

  • Company
    Xeris Biopharma Holdings, Inc.

    Biopharma company developing treatments for rare diseases.

  • Officer
    Beth Hecht

    Company officer executing a 10b5-1 sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

XERS insider trading history →

Related articles

SEP 30
$IOVAMedAI 8/10

Biotech Stocks At 52-Week Highs - IOVA +31%, XERS, GRAL, ABCL, SGHT

Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.

rttnews.com2 min
SEP 29
$XERSMed

Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports

Lundbeck (LON:0ND5) has shown interest in acquiring Xeris Pharmaceuticals (NASDAQ:XERS), according to Bloomberg. Xeris, focused on endocrine and rare disease therapies, stated it is not for sale. Lundbeck, specializing in neurological and psychiatric conditions, may expand into rare endocrine disorders through this potential deal. Discussions are preliminary, and no formal offer has been made.

investing.com2 min
AUG 13
$XERSMedAI 8/10

Xeris (XERS) Q2 2026 Earnings Call Transcript

Xeris (XERS) Q2 2026 earnings call said it retired its convertible notes, eliminating nearly $3 million in annual interest expense. The company raised full-year 2026 total revenue guidance to $385 million to $390 million. Q2 net product revenue was $91 million (+34% YoY) and total revenue $92.1 million (+29%). Recorlev net revenue was $56.8 million (+81% YoY), Gvoke about $23 million, and Keveyis nearly $12 million. It also reported new U.S. patent allowances for Keveyis and XP-8121.

yahoo.com7 min
AUG 6
$XERSMed

XERIS BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Xeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 XERIS BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Total revenue increased to over $92 million Net product revenue increased 34% year-over-year to over $91 million Recorlev net revenue increased 81% year-over-year to approximately $57 million Tightens full

SEC EDGAR 8-K6 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min